DISCUSSION  by unknown
Question: In Table 6 you had two PCR or im- 
munochemistry positives with sarcoidosis. However, 
contamination in PCR is a big problem. 
Dr Grayston: There were three positive, two by PCR, 
and I would certainly agree that this is one of the things 
that must be looked at in hture studies of sarcoidosis. 
It is interesting to me that microbiologists want us to 
isolate the organism. The pathologists do not worry at 
all about isolation. They want to see the organism. I do 
not know who supports PCR only, but I am sure there 
are some. 
Question: I recommend always to repeat the whole 
procedure fi-om the beginning of the DNA preparation. 
If it is repeated the PCR test is probably positive. 
Dr Grayston: That is a routine in our laboratory also. 
Question: Do you dunk it is possible to use current 
data for the treatment of chronic diseases as in the case 
of H. pylon? 
Dr Grayston: Only on a carefully controlled experi- 
mental basis. It is not really practical to attempt to 
prevent atherosclerosis, because by 15 years of age many 
persons already have initial atherosclerosis. I believe it 
would be reasonable to consider a treatment t r i q to  
prevent progression of &ease to serious outcomes. 
Atherosclerotic diseases are of such enormous impor- 
tance that exploring methods of control would appear 
to be justified. 
Dr Hammerschlag: Perhaps we are premature 
because even with respiratory infections we do not have 
a lot of experience demonstrating eradication of the 
organism even from the nasopharynx or the throat. 
Very few studies have been done prospectively. A 
multicenter pneumonia study that has just been 
published in the Paediatric Infectious Disease Journal 
compared clarithromycin to erythromycin. Clarithro- 
mycin is 10-fold to 100-fold more active in vitro in 
terms of eradicating the organism h m  the naso- 
pharynx of children. But it was not any better than 
erythromycin (about 79% versus 86% ) for eradication. 
Preliminary data on azithromycin show the same thing, 
with a rate of around 80% for eradication. Most of the 
times there is clinical improvement even though the 
organism is persisting. The major issue is why some 
people are symptomatic and others are not. I think we 
need more studies before you can start looking into 
more exotic applications. 
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